Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2021-03-10 Capital/Financing Update
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document explicitly announces the 'Launch of a Rights Issue to accelerate its R&D programs' and details the terms of a 'capital increase through the issuance of new shares (the "New Shares") with shareholders' preferential subscription rights (PSR)'. Key terms like subscription price, parity, subscription period, and impact on shareholding structure are provided. This content directly relates to fundraising, capital structure changes, and the issuance of new securities, which aligns perfectly with the definition of a Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate financing action.
2021-03-10 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated February 4, 2021, announcing that Onxeo has entered into a Clinical Research Agreement with Institut Curie to conduct a Phase 1b/2 clinical trial for AsiDNA™. It details the purpose of the study, quotes management and investigators, and provides background information on the companies and the drug candidate. This type of announcement, detailing a specific operational or clinical development milestone (like a new trial agreement), is characteristic of a general corporate update or press release. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific regulatory filing like a proxy (DEF 14A) or insider trade (DIRS), it best fits the category for general corporate news or regulatory announcements that don't fit elsewhere. Given the content is a specific announcement about a clinical development, it is most appropriately classified as a Regulatory Filing (RNS) as a general press release/announcement, or potentially a Capital/Financing Update (CAP) if the agreement implied significant financial commitment, but the text focuses purely on the clinical agreement, making RNS the most suitable fallback for a non-financial, non-ESG, non-M&A, non-dividend, non-board change announcement.
2021-02-04 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated February 4, 2021, announcing a clinical research agreement between Onxeo and Institut Curie to conduct a Phase 1b/2 trial evaluating AsiDNA™ in combination with radiotherapy for recurrent high-grade glioma in children. The text details the scientific rationale, the study's objectives, quotes from management and the principal investigator, and provides background information on both companies. This type of announcement, detailing a specific clinical development step (a new trial agreement and its scope), is characteristic of an update aimed at investors and the market regarding the company's pipeline progress. It is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a proxy statement. It is best classified as a general corporate announcement related to R&D and strategy, which fits best under the 'Regulatory Filings' (RNS) category as a general press release, or potentially 'Capital/Financing Update' (CAP) if it involved significant funding, but since it's primarily a clinical development update, RNS is the most appropriate general category for non-specific corporate news releases, although 'LTR' (Legal Proceedings Report) is sometimes used for trial updates, RNS is the standard fallback for press releases not covered elsewhere. Given the options, and that it's a major corporate announcement about a clinical trial, RNS (Regulatory Filings/General Announcement) is the most suitable general classification for this type of press release.
2021-02-04 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled and introduced as a "Letter to Shareholders" which provides a business update, clinical progress, and financial structure overview from the CEO. This content is characteristic of a direct communication to investors regarding company performance and outlook, often released outside of mandatory periodic filings. While it contains financial and operational updates, its primary format and purpose align best with a general investor communication document. Since there is no specific code for a 'Letter to Shareholders', I must evaluate the closest fits: 'ER' (Earnings Release - too detailed/narrative), 'IR' (Interim Report - not a formal financial statement), or 'IP' (Investor Presentation - this is text, not a slide deck). Given the context of a direct, non-periodic update letter to shareholders, and considering the available options, this functions similarly to an Investor Presentation (IP) or a comprehensive update that might accompany an earnings release but is distinct. However, the document explicitly links to a PDF titled '210202-shl-onxeo-feb-2021.pdf' (shl likely meaning shareholder letter) and is presented as a press release announcing the availability of this letter. Because it is an announcement of a specific investor document (the Letter to Shareholders), and not the letter itself, the most appropriate classification under the provided definitions is Report Publication Announcement (RPA), as it announces the publication of a specific report/letter. If the letter itself were the document, 'IP' might be considered, but the structure suggests an announcement of that material.
2021-02-02 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is titled "Onxeo publie une Lettre aux actionnaires et fait le point sur ses développements" (Onxeo publishes a Letter to Shareholders and provides an update on its developments). It explicitly states that the company is publishing its "Lettre aux actionnaires" (Letter to Shareholders) and provides an update on clinical trials and financial structure. A 'Letter to Shareholders' is a direct communication to investors, often summarizing performance and outlook, which aligns closely with the content of an Investor Presentation (IP) or a general update document. Given the detailed clinical pipeline update, management commentary, and the explicit reference to the 'Lettre aux actionnaires' which is linked, the most appropriate classification is Investor Presentation (IP), as it serves the function of presenting key information to investors about strategy and progress, even if titled as a letter. It is not a formal regulatory filing like 10-K or IR, nor is it just a brief announcement (RPA/RNS).
2021-02-02 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated January 28, 2021, announcing that Onxeo has secured 5 million euros in non-dilutive financing via State Guaranteed Loans (PGE) from a group of French banks. This announcement directly concerns the company's financial structure, fundraising activities, and cash runway extension. This aligns perfectly with the definition of 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER) focusing only on results, or a general regulatory filing (RNS).
2021-01-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.